Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday. Shares of Moderna ...

Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

Snopes tried to discredit research as a "rumor" when journalist received early results from conference call between researchers and study participants. Spike still detectable in some participants ...

Moderna has been ordered to pay almost £44,000 after 12-year-olds were encouraged to join Covid vaccine trials with the ...

Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Norovirus infection rates are extremely high this year, raising the question: Why can’t a vaccine protect us from the stomach ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

An epidemiologist said the Franklin County resolution was "based on conspiracy and misinformation against the COVID-19 ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...